Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study

Introduction In adults with moderate-to-severe atopic dermatitis (AD), rocatinlimab demonstrated significant and progressive improvement in clinical measures of disease severity compared with placebo. This post hoc analysis of a phase 2b study was undertaken to understand the disease burden and to a...

Full description

Saved in:
Bibliographic Details
Published inDermatology and therapy Vol. 14; no. 12; pp. 3351 - 3366
Main Authors Gooderham, Melinda, Guttman-Yassky, Emma, Igawa, Ken, Kabashima, Kenji, Esfandiari, Ehsanollah, Rylands, Angela J., Williams, Angela, Nixon, Annabel, Dent, Jennifer E., Simpson, Eric
Format Journal Article
LanguageEnglish
Published Cheshire Springer Healthcare 01.12.2024
Springer
Springer Nature B.V
Adis, Springer Healthcare
Subjects
Adults
Atopic dermatitis
Biological products
Body mass index
Care and treatment
Clinical outcomes
Clinical trials
Demographics
Dermatitis
Dermatology
Dermatology Life Quality Index
Evaluation
Health-related quality of life (HRQL)
Internal Medicine
Medical history
Medicine
Medicine & Public Health
Mental health
Methods
Missing data
Monoclonal antibodies
Oral and Maxillofacial Surgery
Original Research
Plastic Surgery
Pruritus
Quality of life
Quality of Life Research
Rocatinlimab
Skin diseases
Sleep
Sleep disturbance
Topical medication
Variance analysis
Canada
United States > US
Japan
Germany
Sleep disturbance
Pruritus
Atopic dermatitis
Dermatology Life Quality Index
Health-related quality of life (HRQL)
Rocatinlimab
Online AccessGet full text

Cover

Abstract Introduction In adults with moderate-to-severe atopic dermatitis (AD), rocatinlimab demonstrated significant and progressive improvement in clinical measures of disease severity compared with placebo. This post hoc analysis of a phase 2b study was undertaken to understand the disease burden and to assess the impact of rocatinlimab on patient-reported outcomes (PROs). Methods This analysis used baseline data from a multicenter, randomized, double-blind study of adults with moderate-to-severe AD, who completed a Worst Pruritus numerical rating scale (NRS), Sleep Disturbance NRS, and the Dermatology Life Quality Index (DLQI). A mixed model for repeated measures was used to estimate changes in PRO scores from baseline; scores were also compared with clinically meaningful change benchmarks. Results The analysis included 267 subjects, mean (SD) age 37.9 (14.7) years, 40.8% female; 55.1% grade 3 and 44.9% grade 4 Investigator Global Assessment for AD. Mean (SD) scores were: Worst Pruritus NRS 7.5 (1.9), Sleep Disturbance NRS 5.5 (2.9), DLQI total score 12.6 (7.1). Worst Pruritus and Sleep NRS scores had low positive correlations with SCORing AD (SCORAD) score ( r  = 0.44, r  = 0.45 respectively) and negligible correlations with Eczema Area and Severity Index (EASI) score and area affected ( r  < 0.30). DLQI score varied by sex, study country, race, age, longer disease duration, disease severity (EASI and SCORAD), presence of asthma, and Worst Pruritus NRS, Sleep disturbance NRS, and DLQI scores. Rocatinlimab showed benefit on all three PROs, with significant improvements from baseline at the end of the double-blind period (week 18) and active treatment extension (week 36). Benefits were maintained over 20 weeks’ post-treatment follow-up. The benefit of rocatinlimab treatment on PROs is rapid and maintained for at least 20 weeks following treatment completion. Conclusion This analysis demonstrates the importance of characterizing the burden of moderate-to-severe AD from the patient’s perspective, alongside clinical disease measures, to develop a fuller picture of treatment benefit. Trial Registration ClinicalTrials.gov identifier, NCT03703102.
AbstractList Introduction In adults with moderate-to-severe atopic dermatitis (AD), rocatinlimab demonstrated significant and progressive improvement in clinical measures of disease severity compared with placebo. This post hoc analysis of a phase 2b study was undertaken to understand the disease burden and to assess the impact of rocatinlimab on patient-reported outcomes (PROs). Methods This analysis used baseline data from a multicenter, randomized, double-blind study of adults with moderate-to-severe AD, who completed a Worst Pruritus numerical rating scale (NRS), Sleep Disturbance NRS, and the Dermatology Life Quality Index (DLQI). A mixed model for repeated measures was used to estimate changes in PRO scores from baseline; scores were also compared with clinically meaningful change benchmarks. Results The analysis included 267 subjects, mean (SD) age 37.9 (14.7) years, 40.8% female; 55.1% grade 3 and 44.9% grade 4 Investigator Global Assessment for AD. Mean (SD) scores were: Worst Pruritus NRS 7.5 (1.9), Sleep Disturbance NRS 5.5 (2.9), DLQI total score 12.6 (7.1). Worst Pruritus and Sleep NRS scores had low positive correlations with SCORing AD (SCORAD) score (r = 0.44, r = 0.45 respectively) and negligible correlations with Eczema Area and Severity Index (EASI) score and area affected (r < 0.30). DLQI score varied by sex, study country, race, age, longer disease duration, disease severity (EASI and SCORAD), presence of asthma, and Worst Pruritus NRS, Sleep disturbance NRS, and DLQI scores. Rocatinlimab showed benefit on all three PROs, with significant improvements from baseline at the end of the double-blind period (week 18) and active treatment extension (week 36). Benefits were maintained over 20 weeks' post-treatment follow-up. The benefit of rocatinlimab treatment on PROs is rapid and maintained for at least 20 weeks following treatment completion. Conclusion This analysis demonstrates the importance of characterizing the burden of moderate-to-severe AD from the patient's perspective, alongside clinical disease measures, to develop a fuller picture of treatment benefit. Trial Registration ClinicalTrials.gov identifier, NCT03703102.
Abstract Introduction In adults with moderate-to-severe atopic dermatitis (AD), rocatinlimab demonstrated significant and progressive improvement in clinical measures of disease severity compared with placebo. This post hoc analysis of a phase 2b study was undertaken to understand the disease burden and to assess the impact of rocatinlimab on patient-reported outcomes (PROs). Methods This analysis used baseline data from a multicenter, randomized, double-blind study of adults with moderate-to-severe AD, who completed a Worst Pruritus numerical rating scale (NRS), Sleep Disturbance NRS, and the Dermatology Life Quality Index (DLQI). A mixed model for repeated measures was used to estimate changes in PRO scores from baseline; scores were also compared with clinically meaningful change benchmarks. Results The analysis included 267 subjects, mean (SD) age 37.9 (14.7) years, 40.8% female; 55.1% grade 3 and 44.9% grade 4 Investigator Global Assessment for AD. Mean (SD) scores were: Worst Pruritus NRS 7.5 (1.9), Sleep Disturbance NRS 5.5 (2.9), DLQI total score 12.6 (7.1). Worst Pruritus and Sleep NRS scores had low positive correlations with SCORing AD (SCORAD) score (r = 0.44, r = 0.45 respectively) and negligible correlations with Eczema Area and Severity Index (EASI) score and area affected (r < 0.30). DLQI score varied by sex, study country, race, age, longer disease duration, disease severity (EASI and SCORAD), presence of asthma, and Worst Pruritus NRS, Sleep disturbance NRS, and DLQI scores. Rocatinlimab showed benefit on all three PROs, with significant improvements from baseline at the end of the double-blind period (week 18) and active treatment extension (week 36). Benefits were maintained over 20 weeks’ post-treatment follow-up. The benefit of rocatinlimab treatment on PROs is rapid and maintained for at least 20 weeks following treatment completion. Conclusion This analysis demonstrates the importance of characterizing the burden of moderate-to-severe AD from the patient’s perspective, alongside clinical disease measures, to develop a fuller picture of treatment benefit. Trial Registration ClinicalTrials.gov identifier, NCT03703102.
IntroductionIn adults with moderate-to-severe atopic dermatitis (AD), rocatinlimab demonstrated significant and progressive improvement in clinical measures of disease severity compared with placebo. This post hoc analysis of a phase 2b study was undertaken to understand the disease burden and to assess the impact of rocatinlimab on patient-reported outcomes (PROs).MethodsThis analysis used baseline data from a multicenter, randomized, double-blind study of adults with moderate-to-severe AD, who completed a Worst Pruritus numerical rating scale (NRS), Sleep Disturbance NRS, and the Dermatology Life Quality Index (DLQI). A mixed model for repeated measures was used to estimate changes in PRO scores from baseline; scores were also compared with clinically meaningful change benchmarks.ResultsThe analysis included 267 subjects, mean (SD) age 37.9 (14.7) years, 40.8% female; 55.1% grade 3 and 44.9% grade 4 Investigator Global Assessment for AD. Mean (SD) scores were: Worst Pruritus NRS 7.5 (1.9), Sleep Disturbance NRS 5.5 (2.9), DLQI total score 12.6 (7.1). Worst Pruritus and Sleep NRS scores had low positive correlations with SCORing AD (SCORAD) score (r = 0.44, r = 0.45 respectively) and negligible correlations with Eczema Area and Severity Index (EASI) score and area affected (r < 0.30). DLQI score varied by sex, study country, race, age, longer disease duration, disease severity (EASI and SCORAD), presence of asthma, and Worst Pruritus NRS, Sleep disturbance NRS, and DLQI scores. Rocatinlimab showed benefit on all three PROs, with significant improvements from baseline at the end of the double-blind period (week 18) and active treatment extension (week 36). Benefits were maintained over 20 weeks’ post-treatment follow-up. The benefit of rocatinlimab treatment on PROs is rapid and maintained for at least 20 weeks following treatment completion.ConclusionThis analysis demonstrates the importance of characterizing the burden of moderate-to-severe AD from the patient’s perspective, alongside clinical disease measures, to develop a fuller picture of treatment benefit.Trial RegistrationClinicalTrials.gov identifier, NCT03703102.
In adults with moderate-to-severe atopic dermatitis (AD), rocatinlimab demonstrated significant and progressive improvement in clinical measures of disease severity compared with placebo. This post hoc analysis of a phase 2b study was undertaken to understand the disease burden and to assess the impact of rocatinlimab on patient-reported outcomes (PROs).INTRODUCTIONIn adults with moderate-to-severe atopic dermatitis (AD), rocatinlimab demonstrated significant and progressive improvement in clinical measures of disease severity compared with placebo. This post hoc analysis of a phase 2b study was undertaken to understand the disease burden and to assess the impact of rocatinlimab on patient-reported outcomes (PROs).This analysis used baseline data from a multicenter, randomized, double-blind study of adults with moderate-to-severe AD, who completed a Worst Pruritus numerical rating scale (NRS), Sleep Disturbance NRS, and the Dermatology Life Quality Index (DLQI). A mixed model for repeated measures was used to estimate changes in PRO scores from baseline; scores were also compared with clinically meaningful change benchmarks.METHODSThis analysis used baseline data from a multicenter, randomized, double-blind study of adults with moderate-to-severe AD, who completed a Worst Pruritus numerical rating scale (NRS), Sleep Disturbance NRS, and the Dermatology Life Quality Index (DLQI). A mixed model for repeated measures was used to estimate changes in PRO scores from baseline; scores were also compared with clinically meaningful change benchmarks.The analysis included 267 subjects, mean (SD) age 37.9 (14.7) years, 40.8% female; 55.1% grade 3 and 44.9% grade 4 Investigator Global Assessment for AD. Mean (SD) scores were: Worst Pruritus NRS 7.5 (1.9), Sleep Disturbance NRS 5.5 (2.9), DLQI total score 12.6 (7.1). Worst Pruritus and Sleep NRS scores had low positive correlations with SCORing AD (SCORAD) score (r = 0.44, r = 0.45 respectively) and negligible correlations with Eczema Area and Severity Index (EASI) score and area affected (r < 0.30). DLQI score varied by sex, study country, race, age, longer disease duration, disease severity (EASI and SCORAD), presence of asthma, and Worst Pruritus NRS, Sleep disturbance NRS, and DLQI scores. Rocatinlimab showed benefit on all three PROs, with significant improvements from baseline at the end of the double-blind period (week 18) and active treatment extension (week 36). Benefits were maintained over 20 weeks' post-treatment follow-up. The benefit of rocatinlimab treatment on PROs is rapid and maintained for at least 20 weeks following treatment completion.RESULTSThe analysis included 267 subjects, mean (SD) age 37.9 (14.7) years, 40.8% female; 55.1% grade 3 and 44.9% grade 4 Investigator Global Assessment for AD. Mean (SD) scores were: Worst Pruritus NRS 7.5 (1.9), Sleep Disturbance NRS 5.5 (2.9), DLQI total score 12.6 (7.1). Worst Pruritus and Sleep NRS scores had low positive correlations with SCORing AD (SCORAD) score (r = 0.44, r = 0.45 respectively) and negligible correlations with Eczema Area and Severity Index (EASI) score and area affected (r < 0.30). DLQI score varied by sex, study country, race, age, longer disease duration, disease severity (EASI and SCORAD), presence of asthma, and Worst Pruritus NRS, Sleep disturbance NRS, and DLQI scores. Rocatinlimab showed benefit on all three PROs, with significant improvements from baseline at the end of the double-blind period (week 18) and active treatment extension (week 36). Benefits were maintained over 20 weeks' post-treatment follow-up. The benefit of rocatinlimab treatment on PROs is rapid and maintained for at least 20 weeks following treatment completion.This analysis demonstrates the importance of characterizing the burden of moderate-to-severe AD from the patient's perspective, alongside clinical disease measures, to develop a fuller picture of treatment benefit.CONCLUSIONThis analysis demonstrates the importance of characterizing the burden of moderate-to-severe AD from the patient's perspective, alongside clinical disease measures, to develop a fuller picture of treatment benefit.ClinicalTrials.gov identifier, NCT03703102.TRIAL REGISTRATIONClinicalTrials.gov identifier, NCT03703102.
Introduction In adults with moderate-to-severe atopic dermatitis (AD), rocatinlimab demonstrated significant and progressive improvement in clinical measures of disease severity compared with placebo. This post hoc analysis of a phase 2b study was undertaken to understand the disease burden and to assess the impact of rocatinlimab on patient-reported outcomes (PROs). Methods This analysis used baseline data from a multicenter, randomized, double-blind study of adults with moderate-to-severe AD, who completed a Worst Pruritus numerical rating scale (NRS), Sleep Disturbance NRS, and the Dermatology Life Quality Index (DLQI). A mixed model for repeated measures was used to estimate changes in PRO scores from baseline; scores were also compared with clinically meaningful change benchmarks. Results The analysis included 267 subjects, mean (SD) age 37.9 (14.7) years, 40.8% female; 55.1% grade 3 and 44.9% grade 4 Investigator Global Assessment for AD. Mean (SD) scores were: Worst Pruritus NRS 7.5 (1.9), Sleep Disturbance NRS 5.5 (2.9), DLQI total score 12.6 (7.1). Worst Pruritus and Sleep NRS scores had low positive correlations with SCORing AD (SCORAD) score ( r  = 0.44, r  = 0.45 respectively) and negligible correlations with Eczema Area and Severity Index (EASI) score and area affected ( r  < 0.30). DLQI score varied by sex, study country, race, age, longer disease duration, disease severity (EASI and SCORAD), presence of asthma, and Worst Pruritus NRS, Sleep disturbance NRS, and DLQI scores. Rocatinlimab showed benefit on all three PROs, with significant improvements from baseline at the end of the double-blind period (week 18) and active treatment extension (week 36). Benefits were maintained over 20 weeks’ post-treatment follow-up. The benefit of rocatinlimab treatment on PROs is rapid and maintained for at least 20 weeks following treatment completion. Conclusion This analysis demonstrates the importance of characterizing the burden of moderate-to-severe AD from the patient’s perspective, alongside clinical disease measures, to develop a fuller picture of treatment benefit. Trial Registration ClinicalTrials.gov identifier, NCT03703102.
In adults with moderate-to-severe atopic dermatitis (AD), rocatinlimab demonstrated significant and progressive improvement in clinical measures of disease severity compared with placebo. This post hoc analysis of a phase 2b study was undertaken to understand the disease burden and to assess the impact of rocatinlimab on patient-reported outcomes (PROs). This analysis used baseline data from a multicenter, randomized, double-blind study of adults with moderate-to-severe AD, who completed a Worst Pruritus numerical rating scale (NRS), Sleep Disturbance NRS, and the Dermatology Life Quality Index (DLQI). A mixed model for repeated measures was used to estimate changes in PRO scores from baseline; scores were also compared with clinically meaningful change benchmarks. The analysis included 267 subjects, mean (SD) age 37.9 (14.7) years, 40.8% female; 55.1% grade 3 and 44.9% grade 4 Investigator Global Assessment for AD. Mean (SD) scores were: Worst Pruritus NRS 7.5 (1.9), Sleep Disturbance NRS 5.5 (2.9), DLQI total score 12.6 (7.1). Worst Pruritus and Sleep NRS scores had low positive correlations with SCORing AD (SCORAD) score (r = 0.44, r = 0.45 respectively) and negligible correlations with Eczema Area and Severity Index (EASI) score and area affected (r < 0.30). DLQI score varied by sex, study country, race, age, longer disease duration, disease severity (EASI and SCORAD), presence of asthma, and Worst Pruritus NRS, Sleep disturbance NRS, and DLQI scores. Rocatinlimab showed benefit on all three PROs, with significant improvements from baseline at the end of the double-blind period (week 18) and active treatment extension (week 36). Benefits were maintained over 20 weeks' post-treatment follow-up. The benefit of rocatinlimab treatment on PROs is rapid and maintained for at least 20 weeks following treatment completion. This analysis demonstrates the importance of characterizing the burden of moderate-to-severe AD from the patient's perspective, alongside clinical disease measures, to develop a fuller picture of treatment benefit.
In adults with moderate-to-severe atopic dermatitis (AD), rocatinlimab demonstrated significant and progressive improvement in clinical measures of disease severity compared with placebo. This post hoc analysis of a phase 2b study was undertaken to understand the disease burden and to assess the impact of rocatinlimab on patient-reported outcomes (PROs). This analysis used baseline data from a multicenter, randomized, double-blind study of adults with moderate-to-severe AD, who completed a Worst Pruritus numerical rating scale (NRS), Sleep Disturbance NRS, and the Dermatology Life Quality Index (DLQI). A mixed model for repeated measures was used to estimate changes in PRO scores from baseline; scores were also compared with clinically meaningful change benchmarks. The analysis included 267 subjects, mean (SD) age 37.9 (14.7) years, 40.8% female; 55.1% grade 3 and 44.9% grade 4 Investigator Global Assessment for AD. Mean (SD) scores were: Worst Pruritus NRS 7.5 (1.9), Sleep Disturbance NRS 5.5 (2.9), DLQI total score 12.6 (7.1). Worst Pruritus and Sleep NRS scores had low positive correlations with SCORing AD (SCORAD) score (r = 0.44, r = 0.45 respectively) and negligible correlations with Eczema Area and Severity Index (EASI) score and area affected (r < 0.30). DLQI score varied by sex, study country, race, age, longer disease duration, disease severity (EASI and SCORAD), presence of asthma, and Worst Pruritus NRS, Sleep disturbance NRS, and DLQI scores. Rocatinlimab showed benefit on all three PROs, with significant improvements from baseline at the end of the double-blind period (week 18) and active treatment extension (week 36). Benefits were maintained over 20 weeks' post-treatment follow-up. The benefit of rocatinlimab treatment on PROs is rapid and maintained for at least 20 weeks following treatment completion. This analysis demonstrates the importance of characterizing the burden of moderate-to-severe AD from the patient's perspective, alongside clinical disease measures, to develop a fuller picture of treatment benefit. ClinicalTrials.gov identifier, NCT03703102.
Audience Academic
Author Gooderham, Melinda
Igawa, Ken
Williams, Angela
Guttman-Yassky, Emma
Dent, Jennifer E.
Nixon, Annabel
Simpson, Eric
Esfandiari, Ehsanollah
Kabashima, Kenji
Rylands, Angela J.
Author_xml – sequence: 1
  givenname: Melinda
  surname: Gooderham
  fullname: Gooderham, Melinda
  email: mgooderham@centrefordermatology.com
  organization: SKiN Centre for Dermatology, Queen’s University and Probity Medical Research
– sequence: 2
  givenname: Emma
  surname: Guttman-Yassky
  fullname: Guttman-Yassky, Emma
  organization: Icahn School of Medicine at Mount Sinai
– sequence: 3
  givenname: Ken
  surname: Igawa
  fullname: Igawa, Ken
  organization: Dokkyo Medical University
– sequence: 4
  givenname: Kenji
  surname: Kabashima
  fullname: Kabashima, Kenji
  organization: Kyoto University
– sequence: 5
  givenname: Ehsanollah
  surname: Esfandiari
  fullname: Esfandiari, Ehsanollah
  organization: Kyowa Kirin International
– sequence: 6
  givenname: Angela J.
  surname: Rylands
  fullname: Rylands, Angela J.
  organization: Kyowa Kirin International
– sequence: 7
  givenname: Angela
  surname: Williams
  fullname: Williams, Angela
  organization: Kyowa Kirin International
– sequence: 8
  givenname: Annabel
  surname: Nixon
  fullname: Nixon, Annabel
  organization: Chilli Consultancy
– sequence: 9
  givenname: Jennifer E.
  surname: Dent
  fullname: Dent, Jennifer E.
  organization: Chilli Consultancy
– sequence: 10
  givenname: Eric
  surname: Simpson
  fullname: Simpson, Eric
  organization: Oregon Health and Science University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39532780$$D View this record in MEDLINE/PubMed
BookMark eNp9Ul1vFCEUnZgaW9f-AR8MiS--UC-w7DC-mLX1o0lNm1afCcPc2dLMDCswNe2vMfGf-Mtkd-tqjREeIJdzzuXcnMfFzuAHLIqnDA4YQPkyMiGlpMCnFJgAQW8fFHucVUArVvKd9V1QxRnsFvsxXkFeJcyEYo-KXVFJwUsFe8X3c29NckPnelOT434Z_DVGcpZrOCR6jksfEjbkdEzW9_nFDWTejF2K5KtLl-SjbzCYhDR5eoHXGJDMk186S44w9FklufiKnGNcU9rge2LIkR_rDumbzg0NOeuMxdrTQz-k4LsuNzu7NBF_fOM1uUhjc_OkeNiaLuL-3TkpPr97--nwAz05fX98OD-hVsoqUWa4ncmZgbYxWBnZKj6rVAOmgloBCtaWzEhpsVGsaUWVhybqqrVGAUgLtZgUxxvdxpsrvQx5JOFGe-P0uuDDQpuQnO1QQw1SSMbAlGwq2qpmUtSmRMYZF7NWZa3XG63lWPfY2DzMYLp7ovdfBnepF_5aMzaDaQU8K7y4Uwj-y4gx6d5Fi11nBvRj1IJxVUpVZheT4vlf0Cs_hiHPSgvOpyDZKgxb1MJkB25ofW5sV6J6rpjiOSDT1ccP_oHKu8He2ZzB1uX6PcKzP51uLf7KWAbwDcAGH2PAdgthoFdZ1pss65xlvc6yvs0ksSHFDB4WGH5b-g_rJ5wU9xs
Cites_doi 10.1186/s41687-020-00265-y
10.1111/1346-8138.12220
10.1016/j.jaip.2019.05.055
10.1016/j.ad.2012.03.008
10.1016/j.anai.2019.07.008
10.1016/S0140-6736(22)02037-2
10.1111/bjd.20783
10.1016/j.jaad.2015.10.043
10.3346/jkms.2012.27.11.1327
10.1111/jdv.16003
10.1111/bjd.18557
10.1177/1203475418758992
10.1016/j.anai.2017.09.076
10.1016/j.jaip.2018.11.043
10.1016/j.jdermsci.2020.06.005
10.1111/j.1365-2133.2005.07050.x
10.1056/NEJMoa1610020
10.1684/ejd.2011.1560
10.1111/bjd.17744
10.1016/j.anai.2018.07.006
10.1111/jdv.14313
10.1007/s12325-024-02802-3
10.1159/000365390
10.1186/s41687-019-0128-z
10.1111/jdv.18050
10.1111/bjd.17243
10.1001/jamadermatol.2018.1572
10.1080/09546634.2024.2345739
10.1080/03007995.2016.1195733
10.1177/20406223211002979
10.2340/00015555-3510
10.1186/s12955-021-01877-8
10.1111/bjd.18296
10.1016/j.anai.2011.02.005
10.1016/j.jid.2018.08.028
10.1111/j.1346-8138.2011.01295.x
10.3390/jcm10122578
10.1016/j.adengl.2014.04.012
10.1016/j.anai.2018.07.004
10.2340/actadv.v103.4426
10.1093/bjd/ljae346
10.3390/pharmaceutics14122753
ContentType Journal Article
Copyright The Author(s) 2024
2024. The Author(s).
COPYRIGHT 2024 Springer
The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2024 2024
Copyright_xml – notice: The Author(s) 2024
– notice: 2024. The Author(s).
– notice: COPYRIGHT 2024 Springer
– notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2024 2024
DBID C6C
AAYXX
CITATION
NPM
3V.
7X7
7XB
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1007/s13555-024-01303-z
DatabaseName Springer Nature OA Free Journals
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Pharma Collection
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

Publicly Available Content Database
MEDLINE - Academic


PubMed
Database_xml – sequence: 1
  dbid: C6C
  name: SpringerOpen
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2190-9172
EndPage 3366
ExternalDocumentID oai_doaj_org_article_0b0535110a7143f9b153ba7e121236f8
PMC11604902
A818200048
39532780
10_1007_s13555_024_01303_z
Genre Journal Article
GeographicLocations Canada
United States--US
Japan
Germany
GeographicLocations_xml – name: Canada
– name: Germany
– name: United States--US
– name: Japan
GrantInformation_xml – fundername: Kyowa Kirin International (UK)
GroupedDBID ---
-A0
0R~
2VQ
3V.
4.4
40G
53G
5VS
7X7
8AO
8FI
8FJ
AAKDD
AAKKN
ABDBF
ABEEZ
ABUWG
ACACY
ACGFS
ACMJI
ACUHS
ACULB
ADBBV
ADINQ
ADRAZ
AFGXO
AFKRA
AHBYD
AHMBA
AHSBF
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
C24
C6C
CCPQU
DIK
EBS
EJD
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
HZ~
IAO
IHR
ITC
KQ8
LGEZI
LOTEE
M48
M~E
NADUK
NXXTH
O9-
OK1
PIMPY
PQQKQ
PROAC
RNS
RPM
RSV
SISQX
SMD
SOJ
U2A
UKHRP
~JE
AAYXX
CITATION
PHGZM
PHGZT
NPM
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c559t-1a2c656a0fdae9a5f82698d0a90b80e31f71a55ced81df393033b9fca8005c0b3
IEDL.DBID M48
ISSN 2193-8210
IngestDate Wed Aug 27 01:31:16 EDT 2025
Thu Aug 21 18:36:28 EDT 2025
Thu Jul 10 20:04:35 EDT 2025
Fri Jul 25 09:09:39 EDT 2025
Thu Apr 17 06:58:45 EDT 2025
Tue Apr 15 04:03:09 EDT 2025
Thu Apr 03 07:02:51 EDT 2025
Tue Jul 01 03:55:21 EDT 2025
Fri Feb 21 02:38:47 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords Sleep disturbance
Pruritus
Atopic dermatitis
Dermatology Life Quality Index
Health-related quality of life (HRQL)
Rocatinlimab
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c559t-1a2c656a0fdae9a5f82698d0a90b80e31f71a55ced81df393033b9fca8005c0b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1007/s13555-024-01303-z
PMID 39532780
PQID 3224051219
PQPubID 2034779
PageCount 16
ParticipantIDs doaj_primary_oai_doaj_org_article_0b0535110a7143f9b153ba7e121236f8
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11604902
proquest_miscellaneous_3128758703
proquest_journals_3224051219
gale_infotracmisc_A818200048
gale_infotracacademiconefile_A818200048
pubmed_primary_39532780
crossref_primary_10_1007_s13555_024_01303_z
springer_journals_10_1007_s13555_024_01303_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-12-01
PublicationDateYYYYMMDD 2024-12-01
PublicationDate_xml – month: 12
  year: 2024
  text: 2024-12-01
  day: 01
PublicationDecade 2020
PublicationPlace Cheshire
PublicationPlace_xml – name: Cheshire
– name: Switzerland
– name: Heidelberg
PublicationSubtitle Research, treatment and aesthetic interventions in dermatology
PublicationTitle Dermatology and therapy
PublicationTitleAbbrev Dermatol Ther (Heidelb)
PublicationTitleAlternate Dermatol Ther (Heidelb)
PublicationYear 2024
Publisher Springer Healthcare
Springer
Springer Nature B.V
Adis, Springer Healthcare
Publisher_xml – name: Springer Healthcare
– name: Springer
– name: Springer Nature B.V
– name: Adis, Springer Healthcare
References Feldman, Guerin, Gauthier-Loiselle (CR43) 2024; 35
Sánchez-Pérez, Daudén-Tello, Mora, Lara (CR10) 2013; 104
de Bruin-Weller, Gadkari, Auziere (CR14) 2019
Silverberg, Gelfand, Margolis (CR18) 2019; 7
Yano, Saeki, Ishiji (CR16) 2013; 40
Newton, DeLozier, Griffiths (CR33) 2019; 3
CR38
Maksimović, Janković, Marinković, Sekulović, Zivković, Spirić (CR19) 2012; 39
Silverberg, DeLozier, Sun (CR29) 2021; 19
CR36
Nakagawa, Iizuka, Nemoto (CR27) 2020; 99
CR31
Thyssen, Halling-Sønderby, Wu, Egeberg (CR7) 2019; 20
Dias-Barbosa, Matos, Vernon, Carney, Krystal, Puelles (CR32) 2020; 4
Girolomoni, de Bruin-Weller, Aoki (CR1) 2021; 12
Silverberg, Gelfand, Margolis (CR4) 2018; 121
Chiesa Fuxench, Block, Boguniewicz (CR9) 2019; 139
Silverberg, Gelfand, Margolis (CR5) 2019; 7
Bobotsis, Fleming, Eshtiaghi, Cresswell-Melville, Drucker (CR12) 2018; 22
Kim, Li, Seo (CR20) 2012; 27
Richard, Paul, Nijsten (CR3) 2022; 36
Whiteley, Emir, Seitzman, Makinson (CR15) 2016; 32
Patel, Singam, Vakharia (CR30) 2019; 180
Guttman-Yassky, Simpson, Reich (CR24) 2023; 401
Papp, Gooderham, Girard, Raman, Strout (CR25) 2017; 31
CR26
Simpson, Bieber, Guttman-Yassky (CR37) 2016; 375
Simpson, Guttman-Yassky, Margolis (CR22) 2018; 154
CR23
Wei, Ghorayeb, Andria (CR13) 2019; 123
CR21
Rams, Baldasaro, Bunod (CR28) 2024; 41
CR42
Bylund, Kobyletzki, Svalstedt, Svensson (CR2) 2020; 100
Basra, Salek, Camilleri, Sturkey, Finlay (CR35) 2015; 230
Torrelo, Ortiz, Alomar, Ros, Prieto, Cuervo (CR11) 2012; 22
Shim, Park, Kim (CR40) 2011; 106
Simpson, Bieber, Eckert (CR8) 2016; 74
Holm, Wulf, Stegmann, Jemec (CR39) 2006; 154
Puelles, Fofana, Rodriguez (CR34) 2022; 186
Yosipovitch, Reaney, Mastey (CR41) 2019; 181
Vakharia, Chopra, Sacotte (CR6) 2017; 119
Andersen, Nyeland, Nyberg (CR17) 2019
EA Holm (1303_CR39) 2006; 154
C Yano (1303_CR16) 2013; 40
G Girolomoni (1303_CR1) 2021; 12
N Maksimović (1303_CR19) 2012; 39
A Rams (1303_CR28) 2024; 41
1303_CR42
1303_CR21
A Torrelo (1303_CR11) 2012; 22
L Andersen (1303_CR17) 2019
1303_CR23
1303_CR26
J Whiteley (1303_CR15) 2016; 32
E Guttman-Yassky (1303_CR24) 2023; 401
R Bobotsis (1303_CR12) 2018; 22
L Newton (1303_CR33) 2019; 3
PP Vakharia (1303_CR6) 2017; 119
ZC Chiesa Fuxench (1303_CR9) 2019; 139
KR Patel (1303_CR30) 2019; 180
JI Silverberg (1303_CR4) 2018; 121
JI Silverberg (1303_CR29) 2021; 19
S Bylund (1303_CR2) 2020; 100
J Sánchez-Pérez (1303_CR10) 2013; 104
EL Simpson (1303_CR22) 2018; 154
WH Shim (1303_CR40) 2011; 106
H Nakagawa (1303_CR27) 2020; 99
1303_CR31
MA Richard (1303_CR3) 2022; 36
SR Feldman (1303_CR43) 2024; 35
DH Kim (1303_CR20) 2012; 27
1303_CR36
EL Simpson (1303_CR37) 2016; 375
J Silverberg (1303_CR18) 2019; 7
1303_CR38
M de Bruin-Weller (1303_CR14) 2019
J Silverberg (1303_CR5) 2019; 7
EL Simpson (1303_CR8) 2016; 74
W Wei (1303_CR13) 2019; 123
KA Papp (1303_CR25) 2017; 31
G Yosipovitch (1303_CR41) 2019; 181
JP Thyssen (1303_CR7) 2019; 20
J Puelles (1303_CR34) 2022; 186
C Dias-Barbosa (1303_CR32) 2020; 4
MK Basra (1303_CR35) 2015; 230
References_xml – volume: 4
  start-page: 100
  issue: 1
  year: 2020
  ident: CR32
  article-title: Content validity of a sleep numerical rating scale and a sleep diary in adults and adolescents with moderate-to-severe atopic dermatitis
  publication-title: J Patient Rep Outcomes
  doi: 10.1186/s41687-020-00265-y
– volume: 40
  start-page: 736
  issue: 9
  year: 2013
  end-page: 739
  ident: CR16
  article-title: Impact of disease severity on work productivity and activity impairment in Japanese patients with atopic dermatitis
  publication-title: J Dermatol
  doi: 10.1111/1346-8138.12220
– volume: 7
  start-page: 2699
  issue: 8
  year: 2019
  end-page: 706.e7
  ident: CR5
  article-title: Pain is a common and burdensome symptom of atopic dermatitis in United States adults
  publication-title: J Allergy Clin Immunol Pract
  doi: 10.1016/j.jaip.2019.05.055
– volume: 104
  start-page: 44
  issue: 1
  year: 2013
  end-page: 52
  ident: CR10
  article-title: Impact of atopic dermatitis on health-related quality of life in Spanish children and adults: the PSEDA study
  publication-title: Actas Dermosifiliogr
  doi: 10.1016/j.ad.2012.03.008
– volume: 123
  start-page: 381
  issue: 4
  year: 2019
  end-page: 8.e2
  ident: CR13
  article-title: A real-world study evaluating adeQUacy of existing systemic treatments for patients with moderate-to-severe atopic dermatitis (QUEST-AD): baseline treatment patterns and unmet needs assessment
  publication-title: Ann Allergy Asthma Immunol
  doi: 10.1016/j.anai.2019.07.008
– volume: 401
  start-page: 204
  issue: 10372
  year: 2023
  end-page: 214
  ident: CR24
  article-title: An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(22)02037-2
– volume: 186
  start-page: 285
  issue: 2
  year: 2022
  end-page: 294
  ident: CR34
  article-title: Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate-to-severe atopic dermatitis
  publication-title: Br J Dermatol
  doi: 10.1111/bjd.20783
– volume: 74
  start-page: 491
  issue: 3
  year: 2016
  end-page: 498
  ident: CR8
  article-title: Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults
  publication-title: J Am Acad Dermatol
  doi: 10.1016/j.jaad.2015.10.043
– volume: 27
  start-page: 1327
  issue: 11
  year: 2012
  end-page: 1332
  ident: CR20
  article-title: Quality of life and disease severity are correlated in patients with atopic dermatitis
  publication-title: J Korean Med Sci
  doi: 10.3346/jkms.2012.27.11.1327
– year: 2019
  ident: CR14
  article-title: The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada
  publication-title: J Eur Acad Dermatol Venereol
  doi: 10.1111/jdv.16003
– volume: 20
  start-page: 5
  year: 2019
  ident: CR7
  article-title: Pain severity and use of analgesic medication in adults with atopic dermatitis: a cross-sectional study
  publication-title: Br J Dermatol
  doi: 10.1111/bjd.18557
– volume: 22
  start-page: 445
  issue: 4
  year: 2018
  end-page: 446
  ident: CR12
  article-title: A Canadian adult cross-sectional survey of the burden of moderate to severe atopic dermatitis
  publication-title: J Cutan Med Surg
  doi: 10.1177/1203475418758992
– volume: 119
  start-page: 548
  issue: 6
  year: 2017
  end-page: 52.e3
  ident: CR6
  article-title: Burden of skin pain in atopic dermatitis
  publication-title: Ann A llergy Asthma Immunol
  doi: 10.1016/j.anai.2017.09.076
– volume: 7
  start-page: 1246
  issue: 4
  year: 2019
  end-page: 52.e1
  ident: CR18
  article-title: Health utility scores of atopic dermatitis in US adults
  publication-title: J Allergy Clin Immunol Pract
  doi: 10.1016/j.jaip.2018.11.043
– volume: 99
  start-page: 82
  issue: 2
  year: 2020
  end-page: 89
  ident: CR27
  article-title: Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis
  publication-title: J Dermatol Sci
  doi: 10.1016/j.jdermsci.2020.06.005
– ident: CR42
– ident: CR23
– volume: 154
  start-page: 719
  issue: 4
  year: 2006
  end-page: 725
  ident: CR39
  article-title: Life quality assessment among patients with atopic eczema
  publication-title: Br J Dermatol
  doi: 10.1111/j.1365-2133.2005.07050.x
– volume: 375
  start-page: 2335
  issue: 24
  year: 2016
  end-page: 2348
  ident: CR37
  article-title: Two phase 3 trials of dupilumab versus placebo in atopic dermatitis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1610020
– ident: CR21
– volume: 22
  start-page: 97
  issue: 1
  year: 2012
  end-page: 105
  ident: CR11
  article-title: Atopic dermatitis: impact on quality of life and patients' attitudes toward its management
  publication-title: Eur J Dermatol
  doi: 10.1684/ejd.2011.1560
– volume: 181
  start-page: 761
  issue: 4
  year: 2019
  end-page: 769
  ident: CR41
  article-title: Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis
  publication-title: Br J Dermatol
  doi: 10.1111/bjd.17744
– volume: 121
  start-page: 340
  issue: 3
  year: 2018
  end-page: 347
  ident: CR4
  article-title: Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study
  publication-title: Ann Allergy Asthma Immunol
  doi: 10.1016/j.anai.2018.07.006
– volume: 31
  start-page: 1324
  issue: 8
  year: 2017
  end-page: 1332
  ident: CR25
  article-title: Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis
  publication-title: J Eur Acad Dermatol Venereol
  doi: 10.1111/jdv.14313
– volume: 41
  start-page: 1512
  issue: 4
  year: 2024
  end-page: 1525
  ident: CR28
  article-title: Assessing itch severity: content validity and psychometric properties of a patient-reported pruritus numeric rating scale in atopic dermatitis
  publication-title: Adv Ther
  doi: 10.1007/s12325-024-02802-3
– volume: 230
  start-page: 27
  issue: 1
  year: 2015
  end-page: 33
  ident: CR35
  article-title: Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data
  publication-title: Dermatology
  doi: 10.1159/000365390
– volume: 3
  start-page: 42
  issue: 1
  year: 2019
  ident: CR33
  article-title: Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis
  publication-title: J Patient Rep Outcomes
  doi: 10.1186/s41687-019-0128-z
– ident: CR38
– volume: 36
  start-page: 1088
  issue: 7
  year: 2022
  end-page: 1096
  ident: CR3
  article-title: Prevalence of most common skin diseases in Europe: a population-based study
  publication-title: J Eur Acad Dermatol Venereol
  doi: 10.1111/jdv.18050
– ident: CR31
– volume: 180
  start-page: 1083
  issue: 5
  year: 2019
  end-page: 1089
  ident: CR30
  article-title: Measurement properties of three assessments of burden used in atopic dermatitis in adults
  publication-title: Br J Dermatol
  doi: 10.1111/bjd.17243
– volume: 154
  start-page: 903
  issue: 8
  year: 2018
  end-page: 912
  ident: CR22
  article-title: Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis
  publication-title: JAMA Dermatol
  doi: 10.1001/jamadermatol.2018.1572
– volume: 35
  start-page: 2345739
  issue: 1
  year: 2024
  ident: CR43
  article-title: Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experiment
  publication-title: J Dermatol Treat
  doi: 10.1080/09546634.2024.2345739
– volume: 32
  start-page: 1645
  issue: 10
  year: 2016
  end-page: 1651
  ident: CR15
  article-title: The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey
  publication-title: Curr Med Res Opin
  doi: 10.1080/03007995.2016.1195733
– volume: 12
  start-page: 20406223211002979
  year: 2021
  ident: CR1
  article-title: Nomenclature and clinical phenotypes of atopic dermatitis
  publication-title: Ther Adv Chronic Dis
  doi: 10.1177/20406223211002979
– volume: 100
  start-page: 160
  issue: 12
  year: 2020
  ident: CR2
  article-title: Prevalence and incidence of atopic dermatitis: a systematic review
  publication-title: Acta Derm Venereol
  doi: 10.2340/00015555-3510
– ident: CR36
– volume: 19
  start-page: 247
  issue: 1
  year: 2021
  ident: CR29
  article-title: Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis
  publication-title: Health Qual Life Outcomes
  doi: 10.1186/s12955-021-01877-8
– year: 2019
  ident: CR17
  article-title: Increasing severity of atopic dermatitis is associated with a negative impact on work productivity among adults with atopic dermatitis in France, Germany, the UK and the USA
  publication-title: Br J Dermatol
  doi: 10.1111/bjd.18296
– volume: 106
  start-page: 540
  issue: 6
  year: 2011
  end-page: 541
  ident: CR40
  article-title: Does the EASI score reflect itch severity?
  publication-title: Ann Allergy Asthma Immunol
  doi: 10.1016/j.anai.2011.02.005
– ident: CR26
– volume: 139
  start-page: 583
  issue: 3
  year: 2019
  end-page: 590
  ident: CR9
  article-title: Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population
  publication-title: J Invest Dermatol
  doi: 10.1016/j.jid.2018.08.028
– volume: 39
  start-page: 42
  issue: 1
  year: 2012
  end-page: 47
  ident: CR19
  article-title: Health-related quality of life in patients with atopic dermatitis
  publication-title: J Dermatol
  doi: 10.1111/j.1346-8138.2011.01295.x
– volume: 20
  start-page: 5
  year: 2019
  ident: 1303_CR7
  publication-title: Br J Dermatol
  doi: 10.1111/bjd.18557
– volume: 154
  start-page: 719
  issue: 4
  year: 2006
  ident: 1303_CR39
  publication-title: Br J Dermatol
  doi: 10.1111/j.1365-2133.2005.07050.x
– volume: 40
  start-page: 736
  issue: 9
  year: 2013
  ident: 1303_CR16
  publication-title: J Dermatol
  doi: 10.1111/1346-8138.12220
– volume: 104
  start-page: 44
  issue: 1
  year: 2013
  ident: 1303_CR10
  publication-title: Actas Dermosifiliogr
  doi: 10.1016/j.ad.2012.03.008
– ident: 1303_CR23
  doi: 10.3390/jcm10122578
– volume: 22
  start-page: 97
  issue: 1
  year: 2012
  ident: 1303_CR11
  publication-title: Eur J Dermatol
  doi: 10.1684/ejd.2011.1560
– volume: 39
  start-page: 42
  issue: 1
  year: 2012
  ident: 1303_CR19
  publication-title: J Dermatol
  doi: 10.1111/j.1346-8138.2011.01295.x
– volume: 186
  start-page: 285
  issue: 2
  year: 2022
  ident: 1303_CR34
  publication-title: Br J Dermatol
  doi: 10.1111/bjd.20783
– ident: 1303_CR21
  doi: 10.1016/j.adengl.2014.04.012
– volume: 36
  start-page: 1088
  issue: 7
  year: 2022
  ident: 1303_CR3
  publication-title: J Eur Acad Dermatol Venereol
  doi: 10.1111/jdv.18050
– volume: 12
  start-page: 204062232110029
  year: 2021
  ident: 1303_CR1
  publication-title: Ther Adv Chronic Dis
  doi: 10.1177/20406223211002979
– volume: 27
  start-page: 1327
  issue: 11
  year: 2012
  ident: 1303_CR20
  publication-title: J Korean Med Sci
  doi: 10.3346/jkms.2012.27.11.1327
– ident: 1303_CR38
  doi: 10.1016/j.anai.2018.07.004
– volume: 22
  start-page: 445
  issue: 4
  year: 2018
  ident: 1303_CR12
  publication-title: J Cutan Med Surg
  doi: 10.1177/1203475418758992
– volume: 7
  start-page: 1246
  issue: 4
  year: 2019
  ident: 1303_CR18
  publication-title: J Allergy Clin Immunol Pract
  doi: 10.1016/j.jaip.2018.11.043
– volume: 180
  start-page: 1083
  issue: 5
  year: 2019
  ident: 1303_CR30
  publication-title: Br J Dermatol
  doi: 10.1111/bjd.17243
– volume: 3
  start-page: 42
  issue: 1
  year: 2019
  ident: 1303_CR33
  publication-title: J Patient Rep Outcomes
  doi: 10.1186/s41687-019-0128-z
– volume: 181
  start-page: 761
  issue: 4
  year: 2019
  ident: 1303_CR41
  publication-title: Br J Dermatol
  doi: 10.1111/bjd.17744
– volume: 154
  start-page: 903
  issue: 8
  year: 2018
  ident: 1303_CR22
  publication-title: JAMA Dermatol
  doi: 10.1001/jamadermatol.2018.1572
– volume: 19
  start-page: 247
  issue: 1
  year: 2021
  ident: 1303_CR29
  publication-title: Health Qual Life Outcomes
  doi: 10.1186/s12955-021-01877-8
– volume: 31
  start-page: 1324
  issue: 8
  year: 2017
  ident: 1303_CR25
  publication-title: J Eur Acad Dermatol Venereol
  doi: 10.1111/jdv.14313
– ident: 1303_CR42
  doi: 10.2340/actadv.v103.4426
– year: 2019
  ident: 1303_CR14
  publication-title: J Eur Acad Dermatol Venereol
  doi: 10.1111/jdv.16003
– volume: 4
  start-page: 100
  issue: 1
  year: 2020
  ident: 1303_CR32
  publication-title: J Patient Rep Outcomes
  doi: 10.1186/s41687-020-00265-y
– volume: 100
  start-page: 160
  issue: 12
  year: 2020
  ident: 1303_CR2
  publication-title: Acta Derm Venereol
  doi: 10.2340/00015555-3510
– volume: 7
  start-page: 2699
  issue: 8
  year: 2019
  ident: 1303_CR5
  publication-title: J Allergy Clin Immunol Pract
  doi: 10.1016/j.jaip.2019.05.055
– volume: 375
  start-page: 2335
  issue: 24
  year: 2016
  ident: 1303_CR37
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1610020
– volume: 230
  start-page: 27
  issue: 1
  year: 2015
  ident: 1303_CR35
  publication-title: Dermatology
  doi: 10.1159/000365390
– ident: 1303_CR36
– volume: 106
  start-page: 540
  issue: 6
  year: 2011
  ident: 1303_CR40
  publication-title: Ann Allergy Asthma Immunol
  doi: 10.1016/j.anai.2011.02.005
– volume: 32
  start-page: 1645
  issue: 10
  year: 2016
  ident: 1303_CR15
  publication-title: Curr Med Res Opin
  doi: 10.1080/03007995.2016.1195733
– volume: 123
  start-page: 381
  issue: 4
  year: 2019
  ident: 1303_CR13
  publication-title: Ann Allergy Asthma Immunol
  doi: 10.1016/j.anai.2019.07.008
– ident: 1303_CR31
  doi: 10.1093/bjd/ljae346
– volume: 74
  start-page: 491
  issue: 3
  year: 2016
  ident: 1303_CR8
  publication-title: J Am Acad Dermatol
  doi: 10.1016/j.jaad.2015.10.043
– volume: 401
  start-page: 204
  issue: 10372
  year: 2023
  ident: 1303_CR24
  publication-title: Lancet
  doi: 10.1016/S0140-6736(22)02037-2
– volume: 99
  start-page: 82
  issue: 2
  year: 2020
  ident: 1303_CR27
  publication-title: J Dermatol Sci
  doi: 10.1016/j.jdermsci.2020.06.005
– volume: 41
  start-page: 1512
  issue: 4
  year: 2024
  ident: 1303_CR28
  publication-title: Adv Ther
  doi: 10.1007/s12325-024-02802-3
– volume: 35
  start-page: 2345739
  issue: 1
  year: 2024
  ident: 1303_CR43
  publication-title: J Dermatol Treat
  doi: 10.1080/09546634.2024.2345739
– ident: 1303_CR26
  doi: 10.3390/pharmaceutics14122753
– volume: 121
  start-page: 340
  issue: 3
  year: 2018
  ident: 1303_CR4
  publication-title: Ann Allergy Asthma Immunol
  doi: 10.1016/j.anai.2018.07.006
– year: 2019
  ident: 1303_CR17
  publication-title: Br J Dermatol
  doi: 10.1111/bjd.18296
– volume: 119
  start-page: 548
  issue: 6
  year: 2017
  ident: 1303_CR6
  publication-title: Ann A llergy Asthma Immunol
  doi: 10.1016/j.anai.2017.09.076
– volume: 139
  start-page: 583
  issue: 3
  year: 2019
  ident: 1303_CR9
  publication-title: J Invest Dermatol
  doi: 10.1016/j.jid.2018.08.028
SSID ssj0000706381
Score 2.2984571
Snippet Introduction In adults with moderate-to-severe atopic dermatitis (AD), rocatinlimab demonstrated significant and progressive improvement in clinical measures...
In adults with moderate-to-severe atopic dermatitis (AD), rocatinlimab demonstrated significant and progressive improvement in clinical measures of disease...
Introduction In adults with moderate-to-severe atopic dermatitis (AD), rocatinlimab demonstrated significant and progressive improvement in clinical measures...
IntroductionIn adults with moderate-to-severe atopic dermatitis (AD), rocatinlimab demonstrated significant and progressive improvement in clinical measures of...
Abstract Introduction In adults with moderate-to-severe atopic dermatitis (AD), rocatinlimab demonstrated significant and progressive improvement in clinical...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 3351
SubjectTerms Adults
Atopic dermatitis
Biological products
Body mass index
Care and treatment
Clinical outcomes
Clinical trials
Demographics
Dermatitis
Dermatology
Dermatology Life Quality Index
Evaluation
Health-related quality of life (HRQL)
Internal Medicine
Medical history
Medicine
Medicine & Public Health
Mental health
Methods
Missing data
Monoclonal antibodies
Oral and Maxillofacial Surgery
Original Research
Plastic Surgery
Pruritus
Quality of life
Quality of Life Research
Rocatinlimab
Skin diseases
Sleep
Sleep disturbance
Topical medication
Variance analysis
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k2gICMhcQCLPDYPc9sWqgqpsCpU6s2ynbEaaZtUJHugvwaJf8IvY8bObjdFiAvX2FHieX5jz4wZe2n0TMsydcLVRS1mrkyFRMUQldESAAMKq6k4-ehTcXgy-3ian25d9UU5YaE9cCDc29hQBxJ0Uppu6nbSoIoaXUJCNrdwvswXfd5WMOVtcEmumKIt_HAmKgxsxoqZUDeHXpYKkykBA224uJx4Jd-8_08TveWjrudPXjtE9b7p4A67PYJKPg-LuctuQHuP3Twaj83vs5_HHe3MtcvmXBse9hGg54vQU1UEEA41_7waUABxpGn5nBpz9Jz2abm_MA1BqRg68QVQ-IHPh-6isfw9BMjb9O_4MfT-FapY4ZojNDdLEHuIY2u-oN1604n9kBm_xI8tztCB_vqRGk65jN8fsJODD1_3D8V4O4OwGIUMItGpRTCoY1drkDp3GKjIqo61jE0VQ5a4MtF5bqFGSOwyiXTOjHRWI0TNbWyyh2yn7Vp4zLhMLXI20TYv9cxaaVIoqqx2LkkKMAYi9nrNHXURmnCoq3bLxEuFvFSel-oyYnvEwM1MaqDtH6BYqVGs1L_EKmKviP2K1Bx5jBIbqhXwh6lhlppX1Pme7F_EdiczUT3tdHgtQGo0D73KCEgh1EpkxF5shulNSnlroVvhHEQOGMyhRY7YoyBvmyVlMs_SsoojVk0kcbLm6UjbnPnm4UhSOuxNI_ZmLbRX__V3oj75H0R9ym6lpHQ-G2iX7QzfVvAMMd1gnnv1_Q3WFkag
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4k3agoyExAEsknjzMBe0LVQVUmFVqLQ3y3bsNtKSLE32QH8Ov5QZO7tLiuC6trWx5_XNeGZMyEutJkoUqWOuyis2cUXKBAgGK7US1oJDYRQWJ598zo_PJp_m2XwIuHVDWuVaJ3pFXbUGY-RvOdoesE6JeL_8wfDVKLxdHZ7QuEluYesy5OpiXmxiLMDOwF7oc8Eyzkpwb4a6mVA9B7YWy5MxDQM0Obsa2Sbfwv9vRf2HpbqeRXntKtVbqKN75O4ALek08MJ9csM2D8jtk-Hy_CH5ddpifK5Z1N-VpiGaYDs6C51VWYDitqJfVj0cCYzUDZ1ie46OYrSW-mfTAJqyvmVfLYiApdO-XdaGfrAB-NbdO3pqO78E61aoogDQ9cKyA0CzFZ1hzF637DDkxy_gz2YXYEZpqikmNP58RM6OPn47PGbDEw3MgCvSs0SlBhChil2lrFCZA29FlFWsRKzL2PLEFYnKMmMrwMWOCzhmroUzCnBqZmLNH5Odpm3sU0JFargTiTJZoSbGCJ3avOSVc0mSW61tRF6viSOXoROH3PZcRlJKIKX0pJRXETlA-m1mYhdt_0N7eS4HoZSxxu42AIAUvgLvhAb1r1VhE7TnuSsj8gqpL1HWgcTAtqFkAT4Yu2bJaYnt71EJRmR_NBNk1IyH1_wjBx3RyS1HR-TFZhhXYt5bY9sVzAH4AB4dqOWIPAnsttkSFxlPizKOSDlixNGexyNNfeE7iMOR4o1vGpE3a57dfte_D3X3_9vYI3dSlCaf7LNPdvrLlX0GkK3Xz71c_gZ6_T5l
  priority: 102
  providerName: ProQuest
– databaseName: Springer Journals Complete - Open Access
  dbid: C24
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Jb9QwFLagSIgLYidQkJGQOIClLJPF3KaFqkIqjAqVerNs57mNNCRVkzm0v6YS_4RfxntOMkMKHLjGzua3fc9vMWOvjZ5pmcdOuDIrxczlsZAoGKIwWgKgQ2E1FScffM72j2afjtPjoSisHbPdx5Ck19SbYjc0jVRNTFkTqHjF5U12KyXfnUK0Q42D1785mWHytPCliSjQqRmqZf7-mIlF8o37_1TPv9mn67mT1wKo3i7t3WN3B0DJ5z0H3Gc3oH7Abh8MIfOH7MdhQ7ty9bL6rg3v9xCg5Yu-n6roATiU_Muqw3XAkarmc2rK0XLao-X-sDQEpKJrxFdAxgc-75qzyvIP0MPdqn3PD6H1t1C1CtccYblZgtjBdS75gnbqTSN2-6z4Jb5scYrG8-dVbDjlMV48Ykd7H7_t7ovhZAZh0QPpRKRji0BQh67UIHXq0EmRRRlqGZoihCRyeaTT1EKJcNglEtc5MdJZjfA0taFJHrOtuqnhKeMytomTkbZprmfWShNDViSlc1GUgTEQsLcjddRZ34BDbVotEy0V0lJ5WqrLgO0QAdczqXm2v9Ccn6hBFlVoqKkN4h5Nh787aVDrG51DRGY8c0XA3hD5FYk40hi5ta9UwA-mZllqXlDXe9J9AduezETRtNPhkYHUoBpalRCIQpgVyYC9Wg_TnZTuVkOzwjmIGtCRQ20csCc9v61_KZFpEudFGLBiwomTf56O1NWpbxyOS0qB3jhg70am3XzXvxf12f9Nf87uxCRePudnm2115yt4gcitMy-9oP4CQDY85A
  priority: 102
  providerName: Springer Nature
Title Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study
URI https://link.springer.com/article/10.1007/s13555-024-01303-z
https://www.ncbi.nlm.nih.gov/pubmed/39532780
https://www.proquest.com/docview/3224051219
https://www.proquest.com/docview/3128758703
https://pubmed.ncbi.nlm.nih.gov/PMC11604902
https://doaj.org/article/0b0535110a7143f9b153ba7e121236f8
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1ZbxMxEB71kKq-IG4WSmQkJB7AaO9dIyGUhJYKKSUKROrbyvbaNFLYLTkk2l-DxD_hlzGzR9KU9sVSYm_i9cx4vrHnAHipZChF4ltu8zjnoU18LlAweKqkMAYNCi0pOHlwEh-Pw8-n0ekWtOWOmgWc32jaUT2p8Wz69tfPiw8o8O_XYXCoNCnOmPwpcEvml9uwi5opoYoGgwbuVztzQgqabDCcTsBTNHeaOJqbf2Yf9gIRBX5CSSOvqK0qu___e_gVJXbdwfLaLWulvI7uwp0GdbJuzSb3YMsU92Fv0NyrP4A_o5KO7orp5IdUrD5oMHM2rJOu8hqlm5x9WS6QQ7FnUrAuZe6YMzrIZVVFNUStfFHyrwalw7DuojyfaPbR1Jh4Mn_HRmZePUIhLUwyxO5qangPgW7OhnScr0rer13np_hnwzPUsH9_-4qRs-PFQxgfHX7rH_OmfAPXaKYsuCd9jWhRujaXRsjIoiUj0tyVwlWpawLPJp6MIm1yxMw2ELjkgRJWS8SwkXZV8Ah2irIwT4AJXwdWeFJHiQy1Fso3cRrk1npebJQyDrxuqZOd11k6snU-ZiJrhmTNKrJmlw70iICrkZRhu_qinH3PGoHNXEWZbxAcSaoQb4VC1aBkYjzS9bFNHXhF5M-IM5HGyNJ1OANOmDJqZd2UUuPTBunAwcZIlF-92d0yUNayfxYQ0kIs5gkHXqy66UnyiStMucQxCC3Q2sMt24HHNb-tXqllWwfSDU7ceOfNnmJyVmUXxyWl22DfgTct067ndfuiPr11Ds9g3yehqnyADmBnMVua54jkFqoD26H7CdvkNOnAbu_wZDjCT30_pDbud6oTkk4lxNiO_e4_w79JzQ
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGkIAXxJ3AACOBeABridM0MRJC3cbUsXVMY5P6ZmzHZpVKUpZUaPs5_AB-I-fk0pIheNtr7aR2zu079rkQ8kKrnhIxd8yl_ZT1XMyZAMFgiVbCWnAojMLk5NF-f3jc-ziOxivkV5sLg2GVrU6sFHWaGzwjXw_R9oB1CsT72XeGXaPwdrVtoVGzxa49-wEuW_FuZwvo-5Lz7Q9Hm0PWdBVgBtBzyQLFDYAY5btUWaEiBwBbJKmvhK8T34aBiwMVRcamAOVcKEDHh1o4owBaRcbXIbz3CrkKhtdHZy8ex4szHRAfYGf08WCZIUvAnWrydOpsPbDtmA6NYR_wVnbesYVVy4C_DcMflvFi1OaFq9vKIm7fIjcbKEsHNe_dJis2u0OujZrL-rvk52GO54HZdPJNaVqfXtiCHtSVXFkN_W1KP81LIAGMTDI6wHIgBcXTYVq1aQMozMqcfbYgcpYOynw2MXTL1kB7Urylh7aoHsE8GaooOAR6atkGoOeUHuAdgc7ZZh2PP4U_OzgBs025phhAeXaPHF8K8e6T1SzP7ENCBTehE4EyUax6xgjNbT8JU-eCoG-1th553RJHzurKH3JZ4xlJKYGUsiKlPPfIBtJvMROrdlc_5KdfZaMEpK-xmg4ALoVd553QYG60im2A-KHvEo-8QupL1C1AYhCTOkUCFoxVuuQgwXL7qHQ9staZCTrBdIdb_pGNTirkUoI88nwxjE9inF1m8znMAbgCHiSYAY88qNltsaVQRCGPE98jSYcRO3vujmSTk6piOXxSvGHmHnnT8uxyXf_-qI_-v41n5PrwaLQn93b2dx-TGxwlqwo0WiOr5encPgG4WOqnlYxS8uWylcJvnaB7sA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJ028IO4EBhgJxANYy6VpYiSE2nXVxlipCpP2ZmzHZpVKUpZUaPs5_Ax-Hefk0pIheNtr7aR2zu079rkQ8lzJruSRb5lNegnr2shnHASDxUpyY8Ch0BKTk4_Gvf3j7vuT8GSD_GpyYTCsstGJpaJOMo1n5DsB2h6wTh7fsXVYxGQ4erf4zrCDFN60Nu00KhY5NOc_wH3L3x4MgdYvfH-093l3n9UdBpgGJF0wT_oaAI10bSINl6EFsM3jxJXcVbFrAs9GngxDbRKAdTbgoO8Dxa2WALNC7aoA3nuNbEboFXXI5mBvPJmuTnhAmIC50eODRQcsBueqztqpcvfA0mNyNAaBwHvZRcsylg0E_jYTf9jJyzGcly5yS_s4uklu1MCW9itOvEU2THqbbB3VV_d3yM9phqeD6Xz2TSpanWWYnE6quq6scgRMQj8uCyAIjMxS2sfiIDnFs2JaNm0DYMyKjH0yIICG9otsMdN0aCrYPcvf0KnJy0cwa4ZKCu6Bmhs2ACyd0AneGKiM7VbR-XP4s8kpGHHqK4rhlOd3yfGVkO8e6aRZah4Qyn0dWO5JHUayqzVXvunFQWKt5_WMUsYhrxriiEVVB0SsKz4jKQWQUpSkFBcOGSD9VjOxhnf5Q3b2VdQqQbgKa-sA_JLYg95yBcZHych4iCZ6NnbIS6S-QE0DJAahqRImYMFYs0v0Yyy-jyrYIdutmaAhdHu44R9Ra6hcrOXJIc9Ww_gkRt2lJlvCHAAv4E-CUXDI_YrdVlsKeBj4Uew6JG4xYmvP7ZF0dlrWL4dPivfNvkNeNzy7Xte_P-rD_2_jKdkChSA-HIwPH5HrPgpWGXW0TTrF2dI8BuxYqCe1kFLy5ar1wm_1oIFL
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rocatinlimab+Improves+Patient-Reported+Outcomes+in+Adults+with+Moderate-to-Severe+Atopic+Dermatitis%3A+Results+from+a+Double-Blind+Placebo-Controlled+Phase%C2%A02b+Study&rft.jtitle=Dermatology+and+therapy&rft.au=Gooderham%2C+Melinda&rft.au=Guttman-Yassky%2C+Emma&rft.au=Igawa%2C+Ken&rft.au=Kabashima%2C+Kenji&rft.date=2024-12-01&rft.issn=2193-8210&rft.volume=14&rft.issue=12&rft.spage=3351&rft_id=info:doi/10.1007%2Fs13555-024-01303-z&rft_id=info%3Apmid%2F39532780&rft.externalDocID=39532780
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2193-8210&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2193-8210&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2193-8210&client=summon